Erin L. Schenk

Amber M. Johnson, Erin L. Schenk, A. van Bokhoven, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Evolution of acquired resistance in a ROS1+ KRAS G12C+ NSCLC through the MAPK pathway

Erin L. Schenk, R. Doebele, K. Davies, 2023, npj Precision Oncology.

Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity

Amber M. Johnson, Erin L. Schenk, A. Le, 2023, npj Precision Oncology.

Adaptive immunity is required for durable responses to alectinib in murine models of EML4-ALK lung cancer

Amber M. Johnson, Erin L. Schenk, A. Le, 2022, bioRxiv.

Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo1

Erin L. Schenk, L. Pease, V. V. Van Keulen, 2008, The Journal of Immunology.

Fast-tracked CTL: rapid induction of potent anti-tumor killer T cells in situ.

Erin L. Schenk, L. Pease, K. Heckman, 2007, European journal of immunology.

Safety of Influenza Vaccine in Patients With Cancer Receiving Pembrolizumab.

Erin L. Schenk, I. Riaz, E. Schenk, 2020, JCO oncology practice.

Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma

Erin L. Schenk, A. Dietz, M. Aubry, 2017, Medical Oncology.

Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment

Amber M. Johnson, Erin L. Schenk, L. Heasley, 2021, bioRxiv.

CNS Downstaging: An Emerging Treatment Paradigm for Extensive Brain Metastases in Oncogene-Addicted Lung Cancer.

Erin L. Schenk, P. Bunn, B. Kavanagh, 2023, Lung cancer.

Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2022.2

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blood-Based Biomarkers for Predicting Immunotherapy Benefit in Lung Cancer

Erin L. Schenk, D. Camidge, E. Schenk, 2020, Cell.

A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study.

Erin L. Schenk, J. Nieva, S. Mandrekar, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

CD73 and Adenosine Receptor Signaling as a Potential Therapeutic Target in EGFR-Mutated NSCLC.

Erin L. Schenk, E. Schenk, J. Pacheco, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

Erin L. Schenk, K. Flatten, B. Smith, 2012, Clinical Cancer Research.

Cancer Therapy : Preclinical Effects of Selective Checkpoint Kinase 1 Inhibition on Cytarabine Cytotoxicity in Acute Myelogenous Leukemia Cells In Vitro

Erin L. Schenk, K. Flatten, B. Smith, 2012 .

CDK4/6 inhibition alone and in combination for non-small cell lung cancer

Erin L. Schenk, E. Schenk, J. Pacheco, 2019, Oncotarget.

Disparate binding of chaperone proteins by HLA-A subtypes

Erin L. Schenk, W. Hildebrand, H. Turnquist, 2002, Immunogenetics.

Narrative review: immunotherapy in anaplastic lymphoma kinase (ALK)+ lung cancer—current status and future directions

Erin L. Schenk, 2023, Translational lung cancer research.

Autoimmune Effectors In Vitro and In Vivo Antigen-Specific + Become IL-17 T Regulatory Cells + Reprogrammed FoxP 3

Erin L. Schenk, L. Pease, M. Bell, 2008 .

LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR Exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1/ERBB gene fusions

Erin L. Schenk, T. Burns, D. Camidge, 2020 .

Cancer cell-specific MHCII expression as a determinant of the immune infiltrate organization and function in the non-small cell lung cancer tumor microenvironment.

Amber M. Johnson, Erin L. Schenk, L. Heasley, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Tumor-intrinsic response to IFNγ shapes the tumor microenvironment and anti–PD-1 response in NSCLC

Amber M. Johnson, Erin L. Schenk, E. Kleczko, 2019, Life Science Alliance.

HLA class I polymorphism has a dual impact on ligand binding and chaperone interaction.

Erin L. Schenk, W. Hildebrand, H. Turnquist, 2002, Human immunology.

Clinical outcomes of patients on check point inhibitor therapy who receive routine vaccinations.

Erin L. Schenk, E. Schenk, 2017 .

Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2023.3

Erin L. Schenk, Nofisat Ismaila, L. Sequist, 2024, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Tumor Microenvironment CD14+ Cells Correlate with Poor Overall Survival in Patients with Early-Stage Lung Adenocarcinoma

Erin L. Schenk, A. Dietz, J. Boland, 2022, Cancers.

Retraction: Reprogrammed FoxP3+ T Regulatory Cells Become IL-17+ Antigen-Specific Autoimmune Effectors In Vitro and In Vivo

Erin L. Schenk, L. Pease, V. V. Van Keulen, 2010, The Journal of Immunology.